公开(公告)号：US20230174647A1

公开(公告)日：2023-06-08

申请号：US17845742

申请日：2022-06-21

申请人： Five Prime Therapeutics, Inc. ,  Bristol-Myers Squibb Company

发明人： Xiao Min Schebye ,  Diana Yuhui Chen ,  Andrew Rankin ,  Xiaodi Deng ,  Joseph Toth ,  Linda Liang ,  Michelle Minhua Han ,  Christine Bee ,  Hong-An Truong ,  Mark J. Selby ,  Nils Lonberg ,  Guodong Chen ,  Richard Y. Huang ,  Ekaterina G. Deyanova ,  Alan J. Korman

IPC分类号： C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  A61K39/395 ,  A61K45/06 ,  G01N33/563 ,  G01N33/577

CPC分类号： C07K16/2803 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6803 ,  A61P35/00 ,  C07K16/2827 ,  G01N33/563 ,  G01N33/577 ,  A61K2039/505

摘要： The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.

公开(公告)号：US10898556B2

公开(公告)日：2021-01-26

申请号：US15946625

申请日：2018-04-05

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： John J. Engelhardt ,  Mark J. Selby ,  Alan J. Korman ,  Mary Diane Feingersh ,  Brenda L. Stevens

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K39/00 ,  A61P35/00

摘要： The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer. Accordingly, the antibodies can be used in therapeutic applications and methods to detect ICOS protein.

公开(公告)号：US10653791B2

公开(公告)日：2020-05-19

申请号：US15520954

申请日：2015-11-19

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Nils Lonberg ,  Alan J. Korman ,  Mark J. Selby ,  Bryan C. Barnhart ,  Aaron P. Yamniuk ,  Mohan Srinivasan ,  Karla A. Henning ,  Michelle Minhua Han ,  Ming Lei ,  Liang Schweizer ,  Sandra V. Hatcher ,  Arvind Rajpal

IPC分类号： C07K16/00 ,  C07K16/28 ,  C07K16/30 ,  A61K47/68 ,  A61K39/395

摘要： Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.

公开(公告)号：US10081681B2

公开(公告)日：2018-09-25

申请号：US15021102

申请日：2014-09-18

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Alan J. Korman ,  Nils Lonberg ,  David J. Fontana ,  Andres A. Gutierrez ,  Mark J. Selby ,  Katherine E. Lewis

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K39/00

CPC分类号： C07K16/2818 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/54 ,  A61K2039/545 ,  A61P35/00 ,  C07K16/2803 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/94

摘要： Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-LAG-3 antibody in combination with an anti-PD-1 antibody.

公开(公告)号：US12110337B2

公开(公告)日：2024-10-08

申请号：US17045143

申请日：2019-04-03

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Li-Sheng Lu ,  Mark J. Selby ,  Alan J. Korman ,  Shrikant Deshpande ,  Mohan Srinivasan ,  Jun Zhang ,  Haichun Huang ,  Guodong Chen ,  Richard Y. Huang ,  Ekaterina Deyanova

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61K39/00

CPC分类号： C07K16/2878 ,  A61K39/39541 ,  A61P35/00 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/92

摘要： This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.

公开(公告)号：US11591392B2

公开(公告)日：2023-02-28

申请号：US16697653

申请日：2019-11-27

申请人： Bristol-Myers Squibb Company

发明人： Xiao Min Schebye ,  Mark J. Selby ,  Michelle Minhua Han ,  Christine Bee ,  Andy X. Deng ,  Anan Chuntharapai ,  Brigitte Devaux ,  Huiming Li ,  Paul O. Sheppard ,  Alan J. Korman ,  Daniel F. Ardourel ,  Ekaterina Deyanova ,  Richard Huang ,  Guodong Chen ,  Michelle Kuhne ,  Hong-An Truong

IPC分类号： A61P35/00 ,  C07K16/28 ,  C07K16/30 ,  A61K47/68 ,  G01N33/574 ,  A61K39/00

摘要： Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.

公开(公告)号：US11306143B2

公开(公告)日：2022-04-19

申请号：US16314732

申请日：2017-07-05

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Sean E. Doyle ,  Mark J. Selby ,  Eric Chadwick

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61K9/00 ,  A61K39/00

摘要： Provided are methods and compositions for treating cancer using an effective amount of a PD-1 antagonist (e.g., an antibody) in combination with a TIM-4 antagonist (e.g., an antibody).

公开(公告)号：US11084881B2

公开(公告)日：2021-08-10

申请号：US16578987

申请日：2019-09-23

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Changyu Wang ,  Nils Lonberg ,  Alan J. Korman ,  Mark J. Selby ,  Mohan Srinivasan ,  Karla Henning ,  Michelle Minhua Han ,  Guodong Chen ,  Richard Huang ,  Indrani Chakraborty ,  Haichun Huang ,  Susan Wong ,  Huiming Li

IPC分类号： C12N15/13 ,  C07K16/28 ,  A61K39/395 ,  G01N33/68 ,  G01N33/574 ,  A61K39/00 ,  A61K47/68

摘要： Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

公开(公告)号：US10533052B2

公开(公告)日：2020-01-14

申请号：US16017489

申请日：2018-06-25

申请人： Bristol-Myers Squibb Company

发明人： Xiao Min Schebye ,  Mark J. Selby ,  Michelle Minhua Han ,  Christine Bee ,  Andy X. Deng ,  Anan Chuntharapai ,  Brigitte Devaux ,  Huiming Li ,  Paul O. Sheppard ,  Alan J. Korman ,  Daniel F. Ardourel ,  Ekaterina Deyanova ,  Richard Huang ,  Guodong Chen ,  Michelle Kuhne ,  Hong-An Truong

IPC分类号： C07K16/30 ,  C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  G01N33/574 ,  A61K39/00

摘要： Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.

公开(公告)号：US20190382491A1

公开(公告)日：2019-12-19

申请号：US16529230

申请日：2019-08-01

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Maria Jure-Kunkel ,  David M. Berman ,  Alan J. Korman ,  Mark J. Selby ,  Suba Krishnan

IPC分类号： C07K16/28 ,  C07K16/30

摘要： This disclosure provides a method for treating a subject afflicted with a cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an antibody or an antigen-binding portion thereof that specifically binds to PD-1; and (b) an antibody or an antigen-binding portion thereof that specifically binds to CD 137.